The CancerConnect Myelodysplastic Syndrome Newsletter

TraceyS

Stay Current With Myelodysplastic Syndrome Treatment Advances & Connect with Others

CancerConnect publishes daily cancer news, original articles and "tips" on the management of Myelodysplastic Syndrome. These are available in our monthly Myelodysplastic Syndrome newsletter.

Stay Current - Connect With Other Myelodysplastic Syndrome Patients

Join The CancerConnect Community: Connect with others and receive regular updates

Sign up for the Myelodysplastic Syndrome Newsletter Here

Comments

Myelodysplastic Syndrome

FEATURED

COMMUNITY

Treatment of Myelodysplastic Syndrome

Myelodysplastic Syndrome - several new medications now available for treatment.

Cancer Connect

Overview of Myelodysplastic Syndrome

A guide to the signs, symptoms, diagnosis and types of Myelodysplastic Syndromes

Cancer Connect

Magrolimab Anti-CD47 Monoclonal Antibody

Magrolimab Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome

MedMaven

Dacogen™ Effective in Myelodysplastic Syndromes

Dacogen™ can be used as single drug or in combination for the treatment of Myelodysplastic Syndromes including CMML.

Cancer Connect

jhondolero2

Inqovi (cedazuridine) Treatment for Myelodysplastic Syndromes and CMML

FDA Approves New Therapy for Myelodysplastic Syndromes (MDS) That Can Be Taken at Home

MedMaven

Reblozyl® Approved to Treat Anemia for Lower-Risk Myelodysplastic Syndromes

Reblozyl regulates late-stage red blood cell maturation to relieve patients from the burden of regular RBC transfusions

MedMaven

Guadecitabine Treatment for Myelodysplastic Syndromes

Guadecitabine hypomethylating agent shows promise for intermediate-, high-risk myelodysplastic syndrome

MedMaven

Revlimid® Reduces Need for Blood Transfusions in Some Myelodysplastic Syndromes

Cancer Connect

Myeloablative Treatment Regimens Superior to Reduced Intensity Treatment for AML

Myeloablative Treatment Regimens Superior to Reduced Intensity Treatment for AML & MDS Patients

Cancer Connect

Novel Agent may Reverse Resistance to Targeted Therapy in Acute Leukemia and MDS

Cancer Connect